Press Releases

04.03.2018

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

03.29.2018

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

03.23.2018

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers

03.19.2018

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

03.19.2018

BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable Fluorosulfation Reagent

03.12.2018

BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

03.11.2018

Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants

03.09.2018

AM‐Pharma announces Phase II study results of recAP in sepsis‐associated Acute Kidney Injury

03.08.2018

Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

03.07.2018

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.05.2018

Dan R. Littman Elected to Pfizer’s Board of Directors

03.02.2018

Neofluidics Announces Collaboration with Pfizer Inc.